bay3283142
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 11, 2022 (NCT05515432)
Timeline
Indications
Mechanism of action
NPR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06522997 | Phase 2 | Aug 8, 2024 | Bayer |
| NCT06428825 | Phase 1 | Aug 7, 2024 | Bayer |
| NCT06487845 | Phase 1 | Jul 4, 2024 | Bayer |
| NCT06402721 | Phase 1 | May 17, 2024 | Bayer |
| NCT05800444 | Phase 1 | Apr 3, 2023 | Bayer |
| NCT05491642 | Phase 1 | Sep 8, 2022 | Bayer |
| NCT05515432 | Phase 1 | Aug 11, 2022 | Bayer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 7 | 7 | 2 | 2022 |
1 organizations
Page 1 / 1